Vera Therapeutics, Inc. $VERA Shares Sold by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd cut its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 60.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,670 shares of the company’s stock after selling 17,772 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Vera Therapeutics were worth $469,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of VERA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Vera Therapeutics by 7.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock worth $753,000 after purchasing an additional 2,210 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Vera Therapeutics by 22.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock valued at $2,354,000 after buying an additional 17,907 shares during the last quarter. Jane Street Group LLC raised its stake in Vera Therapeutics by 297.1% in the first quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock valued at $999,000 after buying an additional 62,678 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Vera Therapeutics by 550.5% in the second quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock valued at $7,316,000 after buying an additional 262,805 shares in the last quarter. Finally, Legal & General Group Plc lifted its holdings in Vera Therapeutics by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock worth $1,188,000 after buying an additional 825 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently issued reports on VERA. William Blair reaffirmed an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Wedbush raised their target price on Vera Therapeutics from $35.00 to $43.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Guggenheim boosted their target price on Vera Therapeutics from $56.00 to $76.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Evercore set a $91.00 price target on Vera Therapeutics in a report on Friday, May 15th. Finally, TD Cowen upped their price target on Vera Therapeutics from $73.00 to $78.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Vera Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $84.58.

Insider Buying and Selling at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 46,250 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total value of $1,956,375.00. Following the completion of the sale, the chief executive officer directly owned 151,994 shares of the company’s stock, valued at approximately $6,429,346.20. The trade was a 23.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 83,250 shares of company stock valued at $3,337,770. 15.90% of the stock is currently owned by insiders.

Vera Therapeutics Price Performance

Shares of VERA opened at $43.13 on Wednesday. Vera Therapeutics, Inc. has a 1-year low of $19.07 and a 1-year high of $56.05. The stock has a market cap of $3.10 billion, a PE ratio of -7.79 and a beta of 0.92. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64. The firm has a fifty day moving average price of $36.92 and a 200 day moving average price of $40.84.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the prior year, the business posted ($0.81) EPS. As a group, sell-side analysts anticipate that Vera Therapeutics, Inc. will post -6.37 EPS for the current year.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.